



# DISCOVERY

Transforming lives through innovation.



September 22, 2014



## Lupus 2014

### New Targets, New Approaches

**Lupus 2014 -- a Unique and Intensive Collaboration to Improve Treatment  
for Lupus Patients**

*North American Scientific Conference Sponsored by LRI & Pharma Partners*



100 lupus researchers spent three days focused on ways to accelerate lupus research at a by-invitation-only North American Lupus 2014 conference in Quebec, Canada. Supported in part by LRI and a number of pharma partners, the meeting combined formal presentations with discussion and one-on-one interaction to identify problems and promote collaborative solutions to improve treatments and outcomes for lupus patients.

“Key outcomes of Lupus 2014 include the promotion of drug repositioning in lupus, the importance of patient-related outcomes in measuring success and the emerging concept of preventing inflammation-driven damage in lupus.” notes Dr. Paul Fortin, Professor of Medicine and Canada Research Chair on Systemic Autoimmune Rheumatic Diseases, Centre de recherche du CHU de Québec, and Université Laval.

In addition to the formal program, 10 young scientists were selected to participate in a “Master Class” (pictured right) with preeminent lupus thought leaders to help the participants shape their research ideas and share their own experiences in science, emphasizing the importance of asking truly novel and creative research questions.

LRI President and CEO Margaret Dowd comments, “Sponsoring this conference helps further our mission to advance the most innovative science and foster new creative talent in lupus.”



“Many of the field’s leaders started with an LRI Novel Research grant. Their discoveries laid the foundation for us to now integrate every stage of lupus research from fundamental through clinical study to focus on improving treatment today and drive toward prevention and cure tomorrow.”

Lupus 2014 was created by the organizers of The International Congress on Systemic Lupus Erythematosus, the only international meeting dedicated solely to lupus held every two years. In addition to Dr. Fortin, Congress co-chairs are: Drs. John Esdaile, Arthritis Research Centre of Canada, Matthew H. Liang, Harvard Medical School, Peter Lipsky, Editor *Arthritis*

*Research and Therapy, and Daniel J. Wallace, UCLA.*

**About the Lupus Research Institute**

The world's leading private supporter of innovative research in lupus, the LRI champions scientific risk-taking in the hunt for solutions to this complex and dangerous autoimmune disease.

**Lupus Research Institute**

330 Seventh Avenue, Suite 1701, New York, NY 10001

T: 212.812.9881 F: 212.545.1843

e-mail: [Lupus@LupusNY.org](mailto:Lupus@LupusNY.org)

[LupusResearchInstitute.org](http://LupusResearchInstitute.org) | [Privacy Policy](#) | [Email Preferences](#)